Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for japanese patients with advanced non-squamous non-small-cell lung cancer-a retrospective analysis

Teppei Yamaguchi, Toru Nakanishi, Masamichi Hayashi, Sakurako Uozu, Takuya Okamura, Mariko Morishita, Tomoko Takeyama, Tomoyuki Minezawa, Sayako Morikawa, Yoshikazu Niwa, Yuki Mieno, Atsushi Kato, Tami Hoshino, Sumito Isogai, Mitsushi Okazawa, Kazuyoshi Imaizumi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advnced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regicnen in Japanese patients in a daily clinical setting. Methods: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m2) and pernetrexed (500 mg/m2) as a first-line treatment for advanced non-squamous NSCLC. Results: Recorded Grade 3 or 4 hernatological toxicities included neutropenia in 7 cases (17.5%), leukopenia in 5 cases (12.5%), anernia in 1 case (2.5%), thrombocytopenia in 1 case (2.5%), and febrile neutropenia in 1 case (2.5%). Grade 3 or 4 nonhematological toxicities included anorexia in 3 cases (7.5%), infection in 1 case (2.5%), rash in 1 case (2.5%), and increased transaminase expression in 1 case (2.5%). Therefore, the adverse events were mostly mild. There were no treatment- related deaths. The overall response rate was 37.5%, median progression free survival was 5.6 months, and median overall suMval (OS) was 18.8 months. In an epidermal growth factor receptor (EGFR) mutation status subgroup analysis, the median OS of patients with wild-type EGFR or unknown status (n28) was 16.8 months. Conclusion: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC.

Original languageEnglish
Pages (from-to)183-187
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume42
Issue number2
Publication statusPublished - 01-01-2015

Fingerprint

Pemetrexed
Non-Small Cell Lung Carcinoma
Cisplatin
Safety
Epidermal Growth Factor Receptor
Therapeutics
Febrile Neutropenia
Leukopenia
Anorexia
Standard of Care
Transaminases
Exanthema
Neutropenia
Disease-Free Survival
Mutation
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yamaguchi, Teppei ; Nakanishi, Toru ; Hayashi, Masamichi ; Uozu, Sakurako ; Okamura, Takuya ; Morishita, Mariko ; Takeyama, Tomoko ; Minezawa, Tomoyuki ; Morikawa, Sayako ; Niwa, Yoshikazu ; Mieno, Yuki ; Kato, Atsushi ; Hoshino, Tami ; Isogai, Sumito ; Okazawa, Mitsushi ; Imaizumi, Kazuyoshi. / Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for japanese patients with advanced non-squamous non-small-cell lung cancer-a retrospective analysis. In: Japanese Journal of Cancer and Chemotherapy. 2015 ; Vol. 42, No. 2. pp. 183-187.
@article{4d9d6dd75b4f40ed8e99454b7efd0e75,
title = "Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for japanese patients with advanced non-squamous non-small-cell lung cancer-a retrospective analysis",
abstract = "Background: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advnced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regicnen in Japanese patients in a daily clinical setting. Methods: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m2) and pernetrexed (500 mg/m2) as a first-line treatment for advanced non-squamous NSCLC. Results: Recorded Grade 3 or 4 hernatological toxicities included neutropenia in 7 cases (17.5{\%}), leukopenia in 5 cases (12.5{\%}), anernia in 1 case (2.5{\%}), thrombocytopenia in 1 case (2.5{\%}), and febrile neutropenia in 1 case (2.5{\%}). Grade 3 or 4 nonhematological toxicities included anorexia in 3 cases (7.5{\%}), infection in 1 case (2.5{\%}), rash in 1 case (2.5{\%}), and increased transaminase expression in 1 case (2.5{\%}). Therefore, the adverse events were mostly mild. There were no treatment- related deaths. The overall response rate was 37.5{\%}, median progression free survival was 5.6 months, and median overall suMval (OS) was 18.8 months. In an epidermal growth factor receptor (EGFR) mutation status subgroup analysis, the median OS of patients with wild-type EGFR or unknown status (n28) was 16.8 months. Conclusion: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC.",
author = "Teppei Yamaguchi and Toru Nakanishi and Masamichi Hayashi and Sakurako Uozu and Takuya Okamura and Mariko Morishita and Tomoko Takeyama and Tomoyuki Minezawa and Sayako Morikawa and Yoshikazu Niwa and Yuki Mieno and Atsushi Kato and Tami Hoshino and Sumito Isogai and Mitsushi Okazawa and Kazuyoshi Imaizumi",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "42",
pages = "183--187",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "2",

}

Yamaguchi, T, Nakanishi, T, Hayashi, M, Uozu, S, Okamura, T, Morishita, M, Takeyama, T, Minezawa, T, Morikawa, S, Niwa, Y, Mieno, Y, Kato, A, Hoshino, T, Isogai, S, Okazawa, M & Imaizumi, K 2015, 'Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for japanese patients with advanced non-squamous non-small-cell lung cancer-a retrospective analysis', Japanese Journal of Cancer and Chemotherapy, vol. 42, no. 2, pp. 183-187.

Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for japanese patients with advanced non-squamous non-small-cell lung cancer-a retrospective analysis. / Yamaguchi, Teppei; Nakanishi, Toru; Hayashi, Masamichi; Uozu, Sakurako; Okamura, Takuya; Morishita, Mariko; Takeyama, Tomoko; Minezawa, Tomoyuki; Morikawa, Sayako; Niwa, Yoshikazu; Mieno, Yuki; Kato, Atsushi; Hoshino, Tami; Isogai, Sumito; Okazawa, Mitsushi; Imaizumi, Kazuyoshi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 42, No. 2, 01.01.2015, p. 183-187.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for japanese patients with advanced non-squamous non-small-cell lung cancer-a retrospective analysis

AU - Yamaguchi, Teppei

AU - Nakanishi, Toru

AU - Hayashi, Masamichi

AU - Uozu, Sakurako

AU - Okamura, Takuya

AU - Morishita, Mariko

AU - Takeyama, Tomoko

AU - Minezawa, Tomoyuki

AU - Morikawa, Sayako

AU - Niwa, Yoshikazu

AU - Mieno, Yuki

AU - Kato, Atsushi

AU - Hoshino, Tami

AU - Isogai, Sumito

AU - Okazawa, Mitsushi

AU - Imaizumi, Kazuyoshi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advnced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regicnen in Japanese patients in a daily clinical setting. Methods: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m2) and pernetrexed (500 mg/m2) as a first-line treatment for advanced non-squamous NSCLC. Results: Recorded Grade 3 or 4 hernatological toxicities included neutropenia in 7 cases (17.5%), leukopenia in 5 cases (12.5%), anernia in 1 case (2.5%), thrombocytopenia in 1 case (2.5%), and febrile neutropenia in 1 case (2.5%). Grade 3 or 4 nonhematological toxicities included anorexia in 3 cases (7.5%), infection in 1 case (2.5%), rash in 1 case (2.5%), and increased transaminase expression in 1 case (2.5%). Therefore, the adverse events were mostly mild. There were no treatment- related deaths. The overall response rate was 37.5%, median progression free survival was 5.6 months, and median overall suMval (OS) was 18.8 months. In an epidermal growth factor receptor (EGFR) mutation status subgroup analysis, the median OS of patients with wild-type EGFR or unknown status (n28) was 16.8 months. Conclusion: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC.

AB - Background: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advnced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regicnen in Japanese patients in a daily clinical setting. Methods: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m2) and pernetrexed (500 mg/m2) as a first-line treatment for advanced non-squamous NSCLC. Results: Recorded Grade 3 or 4 hernatological toxicities included neutropenia in 7 cases (17.5%), leukopenia in 5 cases (12.5%), anernia in 1 case (2.5%), thrombocytopenia in 1 case (2.5%), and febrile neutropenia in 1 case (2.5%). Grade 3 or 4 nonhematological toxicities included anorexia in 3 cases (7.5%), infection in 1 case (2.5%), rash in 1 case (2.5%), and increased transaminase expression in 1 case (2.5%). Therefore, the adverse events were mostly mild. There were no treatment- related deaths. The overall response rate was 37.5%, median progression free survival was 5.6 months, and median overall suMval (OS) was 18.8 months. In an epidermal growth factor receptor (EGFR) mutation status subgroup analysis, the median OS of patients with wild-type EGFR or unknown status (n28) was 16.8 months. Conclusion: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84930027058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930027058&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 183

EP - 187

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 2

ER -